Who are Dasatinib and blinatumomab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dasatinib-and-blinatumomab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Dasatinib and blinatumomab — Competitive Intelligence Brief

Dasatinib and blinatumomab (Dasatinib and blinatumomab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine-kinase inhibitor and Bispecific monoclonal antibody. Area: Oncology.

phase 2 Tyrosine-kinase inhibitor and Bispecific monoclonal antibody BCR-ABL, c-KIT, PDGFRβ, CD19, CD3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Dasatinib and blinatumomab (Dasatinib and blinatumomab) — Gruppo Italiano Malattie EMatologiche dell'Adulto. Dasatinib is a tyrosine-kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFRβ, while blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dasatinib and blinatumomab TARGET	Dasatinib and blinatumomab	Gruppo Italiano Malattie EMatologiche dell'Adulto	phase 2	Tyrosine-kinase inhibitor and Bispecific monoclonal antibody	BCR-ABL, c-KIT, PDGFRβ, CD19, CD3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine-kinase inhibitor and Bispecific monoclonal antibody class)

Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dasatinib and blinatumomab — Competitive Intelligence Brief. https://druglandscape.com/ci/dasatinib-and-blinatumomab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab